Pfizer Inc. (PFE) P/E Ratio History
Historical price-to-earnings valuation from 1990 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, Pfizer Inc. (PFE) trades at a price-to-earnings ratio of 20.3x, with a stock price of $27.65 and trailing twelve-month earnings per share of $1.37.
The current P/E is roughly in line with its 5-year average of 19.5x. Over the past five years, PFE's P/E has ranged from a low of 8.0x to a high of 81.1x, placing the current valuation at the 80th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, PFE is roughly in line with its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, PFE trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PFE DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Vaccines and plasma-derived therapies peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
MRKMerck & Co., Inc. | $307B | 17.0 | 0.80Best | +8% |
PFEPfizer Inc. | $157B | 20.3 | - | -4% |
GSKGSK plc | $119B | 16.2Lowest | - | +119% |
SNYSanofi | $118B | 20.3 | - | -7% |
GRFSGrifols, S.A. | $2B | 33.5 | - | +156%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $24.90 | $1.36 | 18.3x | -27% |
| FY2025 Q3 | Sun Sep 28 2025 00:00:00 GM | $23.76 | $1.72 | 13.8x | -45% |
| FY2025 Q2 | Sun Jun 29 2025 00:00:00 GM | $24.19 | $1.89 | 12.8x | -49% |
| FY2025 Q1 | Sun Mar 30 2025 00:00:00 GM | $25.21 | $1.38 | 18.3x | -27% |
| FY2024 Q4 | $26.53 | $1.41 | 18.8x | -25% | |
| FY2024 Q3 | Sun Sep 29 2024 00:00:00 GM | $29.09 | $0.74 | 39.3x | +57% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $28.79 | $0.35 | 81.1x | +223% |
| FY2023 Q3 | Sun Oct 01 2023 00:00:00 GM | $33.17 | $1.82 | 18.2x | -27% |
| FY2023 Q2 | Sun Jul 02 2023 00:00:00 GM | $36.68 | $3.75 | 9.8x | -61% |
| FY2023 Q1 | Sun Apr 02 2023 00:00:00 GM | $40.80 | $5.07 | 8.0x | -68% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $51.24 | $5.47 | 9.4x | -63% |
| FY2022 Q3 | Sun Oct 02 2022 00:00:00 GM | $43.76 | $5.19 | 8.4x | -66% |
Average P/E for displayed period: 25.1x
See PFE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PFE Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PFE vs AGIO
See how PFE stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PFE stock overvalued or undervalued?
PFE trades at 20.3x P/E, near its 5-year average of 19.5x. The 80th percentile ranking places valuation within normal historical bounds.
How does PFE's valuation compare to peers?
Pfizer Inc. P/E of 20.3x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is PFE's PEG ratio?
PFE PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1990-2025.